申请人:Bayer Aktiengesellschaft
公开号:US05861404A1
公开(公告)日:1999-01-19
2,9-Disubstituted purin-6-ones are prepared by acylating correspondingly substituted aminoimidazoles in a first step and then cyclizing the product to the purine. The new 2,9-disubstituted purin-6-ones can be employed as active compounds in medicaments, in particular for the treatment of inflammations, thromboembolic and cardiovascular diseases and diseases of the urogenital system.
2,9-二取代嘌呤-6-酮是通过在第一步中酰化相应取代的氨基咪唑,然后将产物环化成嘌呤来制备的。这些新的2,9-二取代嘌呤-6-酮可以作为活性化合物用于药物治疗,特别是用于治疗炎症、血栓栓塞和心血管疾病以及泌尿生殖系统疾病。